These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33220153)

  • 21. Enzyme replacement therapy for mild patients with Gaucher disease.
    Zimran A; Ilan Y; Elstein D
    Am J Hematol; 2009 Apr; 84(4):202-4. PubMed ID: 19229987
    [No Abstract]   [Full Text] [Related]  

  • 22. Thromboelastography Before Epidural Placement in a Thrombocytopenic Parturient With Gaucher Disease Treated With Imiglucerase: A Case Report.
    Tharp WG; Farhang B
    A A Pract; 2018 Jul; 11(1):16-18. PubMed ID: 29634566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
    Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
    Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
    [No Abstract]   [Full Text] [Related]  

  • 24. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic goals in Gaucher disease.
    Mistry P; Germain DP
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
    Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F
    Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of velaglucerase alfa enzyme replacement therapy on red blood cell properties in Gaucher disease.
    Franco M; Reihani N; Marin M; De Person M; Billette de Villemeur T; Rose C; Colin Y; Moussa F; Belmatoug N; Le Van Kim C
    Am J Hematol; 2017 Sep; 92(9):E561-E563. PubMed ID: 28621801
    [No Abstract]   [Full Text] [Related]  

  • 28. Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.
    Brady RO; Murray GJ; Barton NW
    J Inherit Metab Dis; 1994; 17(4):510-9. PubMed ID: 7967500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How I treat Gaucher disease.
    Zimran A
    Blood; 2011 Aug; 118(6):1463-71. PubMed ID: 21670466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term withdrawal from imiglucerase: what can we learn from it?
    Hollak CE
    Blood Cells Mol Dis; 2011 Jan; 46(1):105-6. PubMed ID: 20684887
    [No Abstract]   [Full Text] [Related]  

  • 31. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gaucher's disease and enzyme replacement therapy].
    Cornu F
    Ann Pharm Fr; 1998; 56(3):102-7. PubMed ID: 9770016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
    Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eliglustat for Gaucher's disease: trippingly on the tongue.
    Hughes DA; Pastores GM
    Lancet; 2015 Jun; 385(9985):2328-30. PubMed ID: 25819692
    [No Abstract]   [Full Text] [Related]  

  • 35. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.
    Barranger JA; Brady RO; Grabowski GA; Mankin H; Mistry PK; Weinreb NJ
    Am J Hematol; 2014 May; 89(5):457-8. PubMed ID: 24488939
    [No Abstract]   [Full Text] [Related]  

  • 37. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [First Scandinavian Gaucher meeting. Treatment with enzyme substitution provides optimism for the future].
    Stolt CM
    Nord Med; 1992; 107(11):292-3, 298. PubMed ID: 1448346
    [No Abstract]   [Full Text] [Related]  

  • 39. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y; Ali AS
    J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years].
    Quijada Fraile P; Martín Hernández E; Teresa García-Silva M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():43-5. PubMed ID: 22230125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.